These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 10480154)

  • 1. [Inhibition of gastric secretion by omeprazole and efficacy of calcium carbonate in the control of hyperphosphatemia in patients on maintenance hemodialysis].
    Séchet A; Abighanem O; Said S; Rasombololona M; Morinière P; Brazier M; Fournier A
    Nephrologie; 1999; 20(4):213-6. PubMed ID: 10480154
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of gastric secretion by omeprazole and efficiency of calcium carbonate on the control of hyperphosphatemia in patients on chronic hemodialysis.
    Hardy P; Sechet A; Hottelart C; Oprisiu R; Abighanem O; Said S; Rasombololona M; Brazier M; Moriniere P; Achard JM; Pruna A; Fournier A
    Artif Organs; 1998 Jul; 22(7):569-73. PubMed ID: 9684693
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of calcium carbonate administration timing in relation to food intake on its efficiency in controlling hyperphosphatemia in patients on maintenance dialysis.
    Sechet A; Hardy P; Hottelart C; Rasombololona M; Abighanem O; Oualim Z; Brazier M; Achard JM; Pruna A; Moriniere P; Fournier A
    Artif Organs; 1998 Jul; 22(7):564-8. PubMed ID: 9684692
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Role of the time of administration of calcium carbonate (before or during mealtime) in the control of hyperphosphatemia in patients on maintenance hemodialysis].
    Séchet A; Abighanem O; Said S; Rasombololona M; Morinière P; Brazier M; Fournier A
    Nephrologie; 1999; 20(4):209-12. PubMed ID: 10480153
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Substitution of calcium carbonate for aluminum hydroxide in patients on hemodialysis. Effects on acidosis, on parathyroid function, and on calcemia.
    Anelli A; Brancaccio D; Damasso R; Padovese P; Gallieni M; Garella S
    Nephron; 1989; 52(2):125-32. PubMed ID: 2500612
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of gastric acid suppression with pantoprazole on the efficacy of calcium carbonate as a phosphate binder in haemodialysis patients.
    Cervelli MJ; Shaman A; Meade A; Carroll R; McDonald SP
    Nephrology (Carlton); 2012 Jul; 17(5):458-65. PubMed ID: 22471559
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Comparison of calcium acetate and calcium carbonate for the control of predialysis hyperphosphatemia].
    Djerad M; Morinière P; Westeel PF; el Esper N; Boitte F; Morsli R; Schenouda M; Compagnon M; Achard JM; Fournier A
    Nephrologie; 1991; 12(4):193-7. PubMed ID: 1745337
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aluminum hydroxide, calcium carbonate and calcium acetate in chronic intermittent hemodialysis patients.
    Janssen MJ; van der Kuy A; ter Wee PM; van Boven WP
    Clin Nephrol; 1996 Feb; 45(2):111-9. PubMed ID: 8846523
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term (6 months) cross-over comparison of calcium acetate with calcium carbonate as phosphate binder.
    Ben Hamida F; el Esper I; Compagnon M; Morinière P; Fournier A
    Nephron; 1993; 63(3):258-62. PubMed ID: 8446261
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Can omeprazole reduce the incidence of hypercalcemia in dialysis patients using calcium containing phosphate binders?
    Diskin CJ; Stokes TJ; Dansby LM; Radcliff L; Carter TB
    J Nephrol; 2010; 23(4):438-43. PubMed ID: 20349423
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention of hyperparathyroidism in patients on maintenance dialysis by intravenous 1-alpha-hydroxyvitamin D3 in association with Mg(OH)2 as sole phosphate binder. A randomized comparative study with the association CaCO3 +/- Mg(OH)2.
    Mornière P; Maurouard C; Boudailliez B; Westeel PF; Achard JM; Boitte F; el Esper N; Compagnon M; Maurel G; Bouillon R
    Nephron; 1992; 60(2):154-63. PubMed ID: 1552999
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Control of predialytic hyperphosphatemia by oral calcium acetate and calcium carbonate. Comparable efficacy for half the dose of elemental calcium given as acetate without lower incidence of hypercalcemia.
    Morinière P; Djerad M; Boudailliez B; el Esper N; Boitte F; Westeel PF; Compagnon M; Brazier M; Achard JM; Fournier A
    Nephron; 1992; 60(1):6-11. PubMed ID: 1738415
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Calcium carbonate for the treatment of hyperphosphatemia in chronic hemodialysis patients].
    Kiss D; Battegay M; Meier C; Lyrer A
    Schweiz Med Wochenschr; 1990 Mar; 120(9):295-8. PubMed ID: 2315655
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined therapy with lanthanum carbonate and calcium carbonate for hyperphosphatemia decreases serum FGF-23 level independently of calcium and PTH (COLC Study).
    Shigematsu T; Negi S;
    Nephrol Dial Transplant; 2012 Mar; 27(3):1050-4. PubMed ID: 21771755
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improvement of severe secondary hyperparathyroidism in dialysis patients by intravenous 1 alpha(OH) vitamin D3, oral CaCO3 and low dialysate calcium.
    Moriniere P; el Esper N; Viron B; Judith D; Bourgeon B; Farquet C; Gheerbrant J; Chapuy M; Van Orshoven A; Pamphile R
    Kidney Int Suppl; 1993 Jun; 41():S121-4. PubMed ID: 8320904
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Calcium carbonate is an effective phosphate binder when dialysate calcium concentration is adjusted to control hypercalcemia.
    Mactier RA; Van Stone J; Cox A; Van Stone M; Twardowski Z
    Clin Nephrol; 1987 Nov; 28(5):222-6. PubMed ID: 3427832
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized crossover study comparing the phosphate-binding efficacy of calcium ketoglutarate versus calcium carbonate in patients on chronic hemodialysis.
    Bro S; Rasmussen RA; Handberg J; Olgaard K; Feldt-Rasmussen B
    Am J Kidney Dis; 1998 Feb; 31(2):257-62. PubMed ID: 9469496
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of CAPD and hemodialysis on parathyroid function.
    Malberti F; Corradi B; Imbasciati E
    Adv Perit Dial; 1996; 12():239-44. PubMed ID: 8865912
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-normal calcium (1.35 mmol/l) dialysate in patients on CAPD: efficient and safe long-term control of plasma calcium, phosphate, and parathyroid hormone.
    Bro S; Brandi L; Olgaard K
    Nephrol Dial Transplant; 1996 Aug; 11(8):1586-91. PubMed ID: 8856216
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.